세포 치료 기술 시장 : 제품별, 프로세스별, 세포 유형별, 용도별, 최종 사용자별, 지역별 예측(-2030년)

The global cell therapy technologies market is projected to reach USD 7.91 billion in 2030 from USD 4.41 billion in 2025, with a significant CAGR of 12.4% from 2025 to 2030.

The market is experiencing strong growth, driven by advancements in regenerative medicine, the rising prevalence of chronic diseases, increasing investments in research and development, and innovations in gene editing tools, such as CRISPR. Regulatory support and government funding, along with strategic collaborations between biotech firms and academic institutions, are propelling the development of novel cell therapies, thereby driving market growth.

"The T-cells segment is projected to record the highest CAGR during the forecast period."

The cell therapy technologies market is categorized into three primary categories based on cell type: T cells, stem cells, and other cell types. The T-cell segment is expected to grow at the fastest rate during the forecast period, driven by the strong clinical and commercial momentum of CAR-T and TCR therapies in cancer and their expansion into solid tumor indications. Furthermore, increasing regulatory approvals, favorable reimbursement decisions in significant markets, and growing physician familiarity with T-cell immunotherapies are encouraging broader adoption, which in turn boosts demand for specialized media, gene-editing tools, bioreactors, and analytics tailored to T-cell workflows within the cell therapy technology market.

"The cancer application segment accounted for the largest share in 2024."

The application segment in the cell therapy technologies market includes cancer, cardiovascular disease (CVD), orthopaedic disorders, autoimmune diseases, and other applications. The cancer application segment dominated in 2024 due to the increasing prevalence of cancer globally and the rising demand for innovative, targeted therapies. Advancements in cell engineering, scalable manufacturing, and emerging applications in solid tumors further enhance the growth potential of this segment. It possesses a solid clinical pipeline, and government initiatives are highly supportive, with regulatory approvals facilitating the segment's growth.

"The US dominated the North American cell therapy technologies market in 2024."

The US is the largest biopharmaceutical market globally and a key hub for cell and gene therapy innovation, making it a core demand center for cell therapy technologies, products, and services. Demand is expected to rise further, supported by a sophisticated research ecosystem, strong venture and public funding, and the presence of foremost CGT technology leaders, including Thermo Fisher Scientific, Danaher, and Merck. The country benefits from substantial NIH and BARDA support for advanced therapies, as well as large precision medicine and population-scale CGT initiatives run through leading academic and cancer centers. The high uptake of automated cell processing platforms, digital manufacturing, and advanced analytics across clinical and commercial facilities reinforces the US market's leadership. In addition, a mature regulatory framework, robust healthcare infrastructure, and active public-private collaborations continue to foster rapid translation and commercialization of new cell therapy technologies in the US.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), Agilent Technologies Inc. (US), Avantor, Inc. (US), Bio-Techne (US), Fresenius SE & Co KGAA (Germany), BD (US), Corning Incorporated (US), Terumo Corporation (Japan), GenScript (US), MaxCyte (US) and STEMCELL Technologies (Canada) are some of the major players operating in the cell therapy technologies market.

Research Coverage:

This research report categorizes the cell therapy technologies market by product (media, sera, and reagents; cell engineering products; cell culture vessels; cell therapy equipment; systems & software; and other products), process (cell processing, cell preservation, cell distribution, cell handling, and process monitoring & quality control), cell type (T-cells, stem cells, and other cells), application (cancer, cardiovascular disease (CVD), orthopedic disorders, autoimmune diseases, and other applications) end user (biopharmaceutical & biotechnology companies, CROs & CMOs, research institutes, and cell banks), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa). The report's scope encompasses detailed information regarding the key factors, including drivers, restraints, challenges, and opportunities, that influence market growth. A thorough analysis of key industry players has provided insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations, and acquisitions are recent developments in the cell therapy technologies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell therapy technologies market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (expanding base of approved CGTs and a growing clinical pipeline, growing capital investments in CGT manufacturing capacity, scale-up of allogeneic and iPSC-derived platforms) restraints (high therapy cost and uncertain reimbursement limiting commercial volumes), opportunities (platformized, modular manufacturing solutions for autologous therapies, integration with digital technologies such as AI & ML), and challenges (lack of skilled workforce in CGT manufacturing and automation) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the cell therapy technologies market.
• Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell therapy technologies market.
• Competitive Assessment: Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW
• 3.2 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT AND COUNTRY, 2024
• 3.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2025 VS. 2030
• 3.4 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Expanding base of approved CGTs and growing clinical pipeline
    • 4.2.1.2 Large capital investments in CGT manufacturing capacity
    • 4.2.1.3 Growing shift towards closed and automated manufacturing
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Manufacturing and logistical complexity
    • 4.2.2.2 High therapy cost and uncertain reimbursement limit commercial volumes
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Platformized and modular manufacturing solutions for autologous therapies
    • 4.2.3.2 Development of personalized and off-the-shelf cell therapies
    • 4.2.3.3 Integration with digital technologies
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Lack of skilled workforce in CGT manufacturing and automation
• 4.3 UNMET NEEDS & WHITE SPACES
• 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER 1/2/3 COMPANIES

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 BARGAINING POWER OF SUPPLIERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS AND FORECAST
  • 5.2.3 TRENDS IN CELL THERAPY TECHNOLOGIES MARKET
  • 5.2.4 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY
  • 5.2.5 R&D TRENDS IN GLOBAL PHARMA INDUSTRY
• 5.3 ECOSYSTEM ANALYSIS
  • 5.3.1 ROLE IN ECOSYSTEM
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.4.2 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT, BY REGION, 2022-2024
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 TRADE ANALYSIS
  • 5.6.1 IMPORT SCENARIO FOR HS CODE 854330
  • 5.6.2 IMPORT VOLUME FOR HS CODE 854330
  • 5.6.3 EXPORT SCENARIO FOR HS CODE 854330, 2020-2024
  • 5.6.4 EXPORT VOLUME FOR HS CODE 854330
• 5.7 KEY CONFERENCES AND EVENTS, 2026
• 5.8 INVESTMENT & FUNDING SCENARIO
• 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.10 IMPACT OF 2025 US TARIFF ON CELL THERAPY TECHNOLOGIES MARKET
  • 5.10.1 KEY TARIFF RATES
  • 5.10.2 PRICE IMPACT ANALYSIS
  • 5.10.3 KEY IMPACT ON COUNTRIES/ REGION
    • 5.10.3.1 US
    • 5.10.3.2 Europe
    • 5.10.3.3 Asia Pacific
  • 5.10.4 END-USE INDUSTRY IMPACT
    • 5.10.4.1 Biopharmaceutical and Biotechnology Companies
    • 5.10.4.2 CROs and CMOs
    • 5.10.4.3 Cell Banks

6 TECHNOLOGICAL ADVANCEMENTS, AI IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1.1 Magnetic-activated cell sorting
    • 6.1.1.2 Cryopreservation
    • 6.1.1.3 Bioprocessing technologies
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Artificial intelligence and machine learning
    • 6.1.2.2 Gene editing technologies
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 Nanotechnology
    • 6.1.3.2 Immunotherapy platforms
• 6.2 TECHNOLOGY/PRODUCT ROADMAP
• 6.3 PATENT ANALYSIS
  • 6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR CELL THERAPY TECHNOLOGIES PATENTS, 2014-2024
• 6.4 FUTURE APPLICATIONS
• 6.5 IMPACT OF AI/GEN AI ON CELL THERAPY TECHNOLOGIES MARKET
  • 6.5.1 TOP USE CASES AND MARKET POTENTIAL
  • 6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN CELL THERAPY TECHNOLOGIES MARKET
  • 6.5.3 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN CELL THERAPY TECHNOLOGIES MARKET

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

• 7.1 REGULATORY LANDSCAPE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
    • 7.1.2.1 North America
    • 7.1.2.2 Europe
    • 7.1.2.3 Asia Pacific
    • 7.1.2.4 Rest of the World
  • 7.1.3 SUSTAINABILITY INITIATIVES, IMPACT, AND REGULATORY POLICY INITIATIVES
  • 7.1.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 KEY STAKEHOLDERS & BUYING CRITERIA
  • 8.2.1 KEY STAKEHOLDERS
  • 8.2.2 BUYING CRITERIA
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES

9 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 MEDIA, SERA, AND REAGENTS
  • 9.2.1 KEY IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET
• 9.3 CELL THERAPY EQUIPMENT
  • 9.3.1 CELL PROCESSING EQUIPMENT
    • 9.3.1.1 Development of automated and closed-system cell processing equipment to accelerate segment growth
  • 9.3.2 SINGLE-USE EQUIPMENT
    • 9.3.2.1 Increasing funding for stem cell therapy to propel market growth
  • 9.3.3 OTHER CELL THERAPY EQUIPMENT
• 9.4 SYSTEMS & SOFTWARE
  • 9.4.1 GROWING NEED FOR CELL THERAPIES TO AID SYSTEMS AND SOFTWARE ADOPTION
• 9.5 CELL CULTURE VESSELS
  • 9.5.1 RISING R&D AND INVESTMENTS IN CELL-BASED THERAPIES TO AUGMENT MARKET DEMAND
• 9.6 CELL ENGINEERING PRODUCTS
  • 9.6.1 AVAILABILITY OF WIDE RANGE OF CELL ENGINEERING PRODUCTS TO SUPPORT MARKET GROWTH
• 9.7 OTHER PRODUCTS

10 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS

• 10.1 INTRODUCTION
• 10.2 CELL PROCESSING
  • 10.2.1 CELL EXPANSION
    • 10.2.1.1 Rising demand for personalized and regenerative therapies to drive market growth
  • 10.2.2 CELL ISOLATION
    • 10.2.2.1 Rising need for scalable and efficient isolation technologies to aid market growth
  • 10.2.3 CELL CHARACTERIZATION
    • 10.2.3.1 Increasing demand for high-quality, safe, and effective cell-based therapies to propel market growth
  • 10.2.4 CELL COLLECTION
    • 10.2.4.1 Advancements in cell collection technologies to propel market growth
• 10.3 CELL PRESERVATION
  • 10.3.1 ADVANCEMENT IN CRYOPRESERVATION TECHNOLOGIES TO BOOST MARKET GROWTH
• 10.4 PROCESS MONITORING & QUALITY CONTROL
  • 10.4.1 INCREASING DEMAND FOR AUTOMATED QUALITY CONTROL IN CELL THERAPY PRODUCTION TO FUEL MARKET GROWTH
• 10.5 CELL HANDLING
  • 10.5.1 INCREASING DEMAND FOR AUTOMATED, EFFICIENT, AND SCALABLE SOLUTIONS TO ACCELERATE MARKET GROWTH
• 10.6 CELL DISTRIBUTION
  • 10.6.1 INCREASED FOCUS ON TRANSPORTATION AND STORAGE TO DRIVE MARKET

11 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE

• 11.1 INTRODUCTION
• 11.2 T CELLS
  • 11.2.1 GROWING RESEARCH ON CAR T-CELL THERAPY TO AID MARKET GROWTH
• 11.3 STEM CELLS
  • 11.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO PROPEL MARKET GROWTH
• 11.4 OTHER CELLS

12 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION

• 12.1 INTRODUCTION
• 12.2 CANCER
  • 12.2.1 FOCUS ON CAR T-CELL INNOVATION TO DRIVE SEGMENT EXPANSION
• 12.3 CARDIOVASCULAR DISEASES
  • 12.3.1 INCREASING FOCUS ON INNOVATIVE CELL THERAPY APPROACHES TO DRIVE MARKET
• 12.4 ORTHOPEDIC DISORDERS
  • 12.4.1 GROWING ADOPTION OF STEM CELL THERAPY FOR TISSUE REPAIR TO SUPPORT MARKET GROWTH
• 12.5 AUTOIMMUNE DISEASES
  • 12.5.1 RISING INVESTMENTS IN STEM CELL RESEARCH TO FUEL MARKET GROWTH
• 12.6 OTHER APPLICATIONS

13 CELL THERAPY TECHNOLOGIES MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 13.2.1 GROWING ADOPTION OF INORGANIC GROWTH STRATEGIES BY BIOPHARMACEUTICAL COMPANIES TO SUPPORT MARKET GROWTH
• 13.3 CROS & CMOS
  • 13.3.1 GROWING FOCUS ON OUTSOURCING CLINICAL-SCALE PRECLINICAL & CLINICAL TRIALS TO DRIVE GROWTH
• 13.4 RESEARCH INSTITUTES
  • 13.4.1 RISING FOCUS ON RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH
• 13.5 CELL BANKS
  • 13.5.1 INCREASING DEMAND FOR STANDARDIZED CELL LINES TO SPUR MARKET GROWTH

14 CELL THERAPY TECHNOLOGIES MARKET, BY REGION

• 14.1 INTRODUCTION
• 14.2 NORTH AMERICA
  • 14.2.1 US
    • 14.2.1.1 US to dominate North American cell therapy technologies market during forecast period
  • 14.2.2 CANADA
    • 14.2.2.1 Favorable funding scenario to drive adoption of cell therapy instruments
• 14.3 EUROPE
  • 14.3.1 GERMANY
    • 14.3.1.1 Well-established pharmaceutical and R&D industry to aid Germany gain significant European market share
  • 14.3.2 UK
    • 14.3.2.1 Favorable funding and investment scenario to fuel market growth
  • 14.3.3 FRANCE
    • 14.3.3.1 Availability of government and private funding to fuel market growth
  • 14.3.4 ITALY
    • 14.3.4.1 Increased focus on public and private investment to offer growth opportunities
  • 14.3.5 SPAIN
    • 14.3.5.1 Advancement in personalized medicines to stimulate market growth
  • 14.3.6 REST OF EUROPE
• 14.4 ASIA PACIFIC
  • 14.4.1 CHINA
    • 14.4.1.1 Focus on innovation and R&D in genetic research to drive market
  • 14.4.2 JAPAN
    • 14.4.2.1 Strong availability of funding for advanced cell therapies to aid market growth
  • 14.4.3 INDIA
    • 14.4.3.1 Substantial government R&D investments and focus of academic institutions on scientific innovation to drive market
  • 14.4.4 SOUTH KOREA
    • 14.4.4.1 Rising number of alliances and investments in research to boost market growth
  • 14.4.5 AUSTRALIA
    • 14.4.5.1 Increasing government funding and initiatives to drive market growth
  • 14.4.6 REST OF ASIA PACIFIC
• 14.5 LATIN AMERICA
  • 14.5.1 BRAZIL
    • 14.5.1.1 Growing development of advanced therapies and robust pharmaceutical & biotechnology sectors to aid market growth
  • 14.5.2 MEXICO
    • 14.5.2.1 Growing pharmaceutical industry and rising government support to aid market growth
  • 14.5.3 REST OF LATIN AMERICA
• 14.6 MIDDLE EAST
  • 14.6.1 GCC COUNTRIES
    • 14.6.1.1 Kingdom of Saudi Arabia
      • 14.6.1.1.1 Increasing government investments in healthcare to support market growth
    • 14.6.1.2 UAE
      • 14.6.1.2.1 Growing R&D expenditure and well-established class infrastructure to spur market growth
    • 14.6.1.3 Rest of GCC Countries
  • 14.6.2 REST OF MIDDLE EAST
• 14.7 AFRICA
  • 14.7.1 INCREASING HEALTH AND RESEARCH SPENDING TO PROPEL MARKET DEMAND FOR ADVANCED CELL THERAPY TECHNOLOGIES

15 COMPETITIVE LANDSCAPE

• 15.1 INTRODUCTION
• 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET
• 15.3 REVENUE ANALYSIS, 2022-2024
• 15.4 MARKET SHARE ANALYSIS, 2024
• 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 15.5.1 STARS
  • 15.5.2 EMERGING LEADERS
  • 15.5.3 PERVASIVE PLAYERS
  • 15.5.4 PARTICIPANTS
  • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 15.5.5.1 Company footprint
    • 15.5.5.2 Region footprint
    • 15.5.5.3 Product footprint
    • 15.5.5.4 Cell type footprint
    • 15.5.5.5 Application footprint
• 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 15.6.1 PROGRESSIVE COMPANIES
  • 15.6.2 RESPONSIVE COMPANIES
  • 15.6.3 DYNAMIC COMPANIES
  • 15.6.4 STARTING BLOCKS
  • 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 15.6.5.1 Detailed list of key startups/SMEs
    • 15.6.5.2 Competitive benchmarking of startups/SMEs
• 15.7 COMPANY VALUATION & FINANCIAL METRICS
  • 15.7.1 FINANCIAL METRICS
  • 15.7.2 COMPANY VALUATION
• 15.8 BRAND/PRODUCT COMPARISON
• 15.9 COMPETITIVE SCENARIO
  • 15.9.1 PRODUCT LAUNCHES
  • 15.9.2 DEALS
  • 15.9.3 EXPANSIONS

16 COMPANY PROFILES

• 16.1 KEY PLAYERS
  • 16.1.1 DANAHER CORPORATION
    • 16.1.1.1 Business overview
    • 16.1.1.2 Products offered
    • 16.1.1.3 Recent developments
      • 16.1.1.3.1 Product launches
      • 16.1.1.3.2 Deals
      • 16.1.1.3.3 Expansions
    • 16.1.1.4 MnM view
      • 16.1.1.4.1 Key strengths
      • 16.1.1.4.2 Strategic choices
      • 16.1.1.4.3 Weaknesses & competitive threats
  • 16.1.2 MERCK KGAA
    • 16.1.2.1 Business overview
    • 16.1.2.2 Products offered
    • 16.1.2.3 Recent developments
      • 16.1.2.3.1 Deals
      • 16.1.2.3.2 Expansions
    • 16.1.2.4 MnM view
      • 16.1.2.4.1 Key strengths
      • 16.1.2.4.2 Strategic choices
      • 16.1.2.4.3 Weaknesses & competitive threats
  • 16.1.3 THERMO FISHER SCIENTIFIC INC.
    • 16.1.3.1 Business overview
    • 16.1.3.2 Products offered
    • 16.1.3.3 Recent developments
      • 16.1.3.3.1 Product launches
      • 16.1.3.3.2 Deals
      • 16.1.3.3.3 Expansions
    • 16.1.3.4 MnM view
      • 16.1.3.4.1 Key strengths
      • 16.1.3.4.2 Strategic choices
      • 16.1.3.4.3 Weaknesses & competitive threats
  • 16.1.4 LONZA
    • 16.1.4.1 Business overview
    • 16.1.4.2 Products offered
    • 16.1.4.3 Recent developments
      • 16.1.4.3.1 Product launches
      • 16.1.4.3.2 Deals
      • 16.1.4.3.3 Expansions
    • 16.1.4.4 MnM view
      • 16.1.4.4.1 Key strengths
      • 16.1.4.4.2 Strategic choices
      • 16.1.4.4.3 Weaknesses & competitive threats
  • 16.1.5 SARTORIUS AG
    • 16.1.5.1 Business overview
    • 16.1.5.2 Products offered
    • 16.1.5.3 Recent developments
      • 16.1.5.3.1 Deals
      • 16.1.5.3.2 Expansions
    • 16.1.5.4 MnM view
      • 16.1.5.4.1 Key strengths
      • 16.1.5.4.2 Strategic choices
      • 16.1.5.4.3 Weaknesses & competitive threats
  • 16.1.6 AGILENT TECHNOLOGIES, INC.
    • 16.1.6.1 Business overview
    • 16.1.6.2 Products offered
    • 16.1.6.3 Recent developments
      • 16.1.6.3.1 Product launches
      • 16.1.6.3.2 Deals
    • 16.1.6.4 MnM view
      • 16.1.6.4.1 Key strengths
      • 16.1.6.4.2 Strategic choices
      • 16.1.6.4.3 Weaknesses & competitive threats
  • 16.1.7 AVANTOR, INC.
    • 16.1.7.1 Business overview
    • 16.1.7.2 Products offered
    • 16.1.7.3 Recent developments
      • 16.1.7.3.1 Product launches
      • 16.1.7.3.2 Deals
  • 16.1.8 FRESENIUS SE & CO. KGAA
    • 16.1.8.1 Business overview
    • 16.1.8.2 Products offered
    • 16.1.8.3 Recent developments
      • 16.1.8.3.1 Deals
  • 16.1.9 BECTON, DICKINSON AND COMPANY (BD)
    • 16.1.9.1 Business overview
    • 16.1.9.2 Products offered
    • 16.1.9.3 Recent developments
      • 16.1.9.3.1 Product launches
      • 16.1.9.3.2 Deals
  • 16.1.10 CORNING INCORPORATED
    • 16.1.10.1 Business overview
    • 16.1.10.2 Products offered
  • 16.1.11 TERUMO CORPORATION
    • 16.1.11.1 Business overview
    • 16.1.11.2 Products offered
    • 16.1.11.3 Recent developments
      • 16.1.11.3.1 Product launches
      • 16.1.11.3.2 Deals
      • 16.1.11.3.3 Expansions
  • 16.1.12 BIO-TECHNE
    • 16.1.12.1 Business overview
    • 16.1.12.2 Products offered
    • 16.1.12.3 Recent developments
      • 16.1.12.3.1 Product launches
      • 16.1.12.3.2 Deals
      • 16.1.12.3.3 Other developments
  • 16.1.13 GENSCRIPT
    • 16.1.13.1 Business overview
    • 16.1.13.2 Products offered
    • 16.1.13.3 Recent developments
      • 16.1.13.3.1 Deals
      • 16.1.13.3.2 Other developments
  • 16.1.14 MAXCYTE
    • 16.1.14.1 Business overview
    • 16.1.14.2 Products offered
    • 16.1.14.3 Recent developments
      • 16.1.14.3.1 Deals
  • 16.1.15 STEMCELL TECHNOLOGIES
    • 16.1.15.1 Business overview
    • 16.1.15.2 Products offered
    • 16.1.15.3 Recent developments
      • 16.1.15.3.1 Product launches
      • 16.1.15.3.2 Deals
• 16.2 OTHER PLAYERS
  • 16.2.1 ROOSTERBIO, INC.
  • 16.2.2 MILTENYI BIOTEC
  • 16.2.3 TRAKCEL
  • 16.2.4 L7 INFORMATICS, INC.
  • 16.2.5 REPLIGEN CORPORATION
  • 16.2.6 MAK SYSTEM
  • 16.2.7 ORIGEN BIOMEDICAL, INC.
  • 16.2.8 IXCELLS BIOTECHNOLOGIES
  • 16.2.9 KORBER AG
  • 16.2.10 KRISHGEN BIOSYSTEMS

17 RESEARCH METHODOLOGY

• 17.1 RESEARCH DATA
  • 17.1.1 SECONDARY DATA
    • 17.1.1.1 Key objectives of secondary research
  • 17.1.2 PRIMARY DATA
    • 17.1.2.1 Breakdown of primaries
    • 17.1.2.2 Objectives of primary research
• 17.2 MARKET ESTIMATION METHODOLOGY
  • 17.2.1 MARKET ESTIMATION
  • 17.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 17.2.3 TOP-DOWN APPROACH
• 17.3 MARKET GROWTH RATE PROJECTIONS
• 17.4 DATA TRIANGULATION
• 17.5 STUDY ASSUMPTIONS
• 17.6 RESEARCH LIMITATIONS
• 17.7 RISK ANALYSIS

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS